Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link. One out of the three major indices are trading lower today with the Dow Jones Industrial Average ( ^DJI) trading down 53 points (-0.3%) at 16,478 as of Wednesday, Jan. 8, 2014, 11:55 AM ET. The NYSE advances/declines ratio sits at 1,242 issues advancing vs. 1,672 declining with 178 unchanged. The Health Care sector currently sits up 0.9% versus the S&P 500, which is unchanged. Top gainers within the sector include Forest Laboratories ( FRX), up 15.6%, Incyte ( INCY), up 5.8%, Alkermes ( ALKS), up 5.7%, Jazz Pharmaceuticals ( JAZZ), up 5.7% and Endo Health Solutions ( ENDP), up 5.4%. A company within the sector that fell today was Humana ( HUM), up 1.4%. TheStreet would like to highlight 5 stocks pushing the sector higher today: 5. Express Scripts ( ESRX) is one of the companies pushing the Health Care sector higher today. As of noon trading, Express Scripts is up $0.55 (0.8%) to $70.39 on average volume. Thus far, 1.8 million shares of Express Scripts exchanged hands as compared to its average daily volume of 4.6 million shares. The stock has ranged in price between $69.61-$70.40 after having opened the day at $70.07 as compared to the previous trading day's close of $69.84. Express Scripts Holding Company provides a range of pharmacy benefit management (PBM) services primarily in the United States and Canada. It offers healthcare management and administration services on behalf of its clients. Express Scripts has a market cap of $56.3 billion and is part of the health services industry. The company has a P/E ratio of 30.2, above the S&P 500 P/E ratio of 17.7. Shares are down 0.6% year to date as of the close of trading on Tuesday. Currently there are 13 analysts that rate Express Scripts a buy, no analysts rate it a sell, and 4 rate it a hold. TheStreet Ratings rates Express Scripts as a buy. The company's strengths can be seen in multiple areas, such as its reasonable valuation levels, good cash flow from operations, largely solid financial position with reasonable debt levels by most measures, solid stock price performance and growth in earnings per share. We feel these strengths outweigh the fact that the company shows low profit margins. Get the full Express Scripts Ratings Report now. 3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.